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Clare Frobisher,1 Michael M Hawkins1 On behalf of the British Childhood Cancer Survivor Study 
Steering Group
ABSTRACT
ObjeCtive
To determine whether modern treatments for cancer 
are associated with a net increased or decreased risk 
of death from neoplastic and non-neoplastic causes 
among survivors of childhood cancer.
Design
Population based cohort study.
setting
British Childhood Cancer Survivor Study.
PartiCiPants
Nationwide population based cohort of 34 489 five 
year survivors of childhood cancer with a diagnosis 
from 1940 to 2006 and followed up until 28 February 
2014.
Main OutCOMe Measures
Cause specific standardised mortality ratios and 
absolute excess risks are reported. Multivariable 
Poisson regression models were utilised to evaluate 
the simultaneous effect of risk factors. Likelihood ratio 
tests were used to test for heterogeneity or trend.
results
Overall, 4475 deaths were observed, which was 9.1 
(95% confidence interval 8.9 to 9.4) times that 
expected in the general population, corresponding to 
64.2 (95% confidence interval 62.1 to 66.3) excess 
deaths per 10 000 person years. The number of excess 
deaths from all causes declined among those treated 
more recently; those treated during 1990-2006 
experienced 30% of the excess number of deaths 
experienced by those treated before 1970. The 
corresponding percentages for the decline in excess 
deaths from recurrence or progression and non-
neoplastic causes were 30% and 60%, respectively. 
Among survivors aged 50-59 years, 41% and 22% of 
excess deaths were attributable to subsequent primary 
neoplasms and circulatory conditions, respectively, 
whereas the corresponding percentages among those 
aged 60 years or more were 31% and 37%.
COnClusiOns
The net effects of changes in cancer treatments, and 
surveillance and management for late effects, over the 
period 1940 to 2006 was to reduce the excess number 
of deaths from both recurrence or progression and 
non-neoplastic causes among those treated more 
recently. Among survivors aged 60 years or more, the 
excess number of deaths from circulatory causes 
exceeds the excess number of deaths from subsequent 
primary neoplasms. The important message for the 
evidence based surveillance aimed at preventing 
excess mortality and morbidity in survivors aged 60 
years or more is that circulatory disease overtakes 
subsequent primary neoplasms as the leading cause 
of excess mortality.
Introduction
Long term survivors of childhood cancer remain at an 
increased risk of mortality when compared with that 
expected from the general population.1-7  Previous 
reports have shown that the principal cause of excess 
mortality in the short term is recurrence or progression 
of the initial cancer,1-3 8  whereas subsequent primary 
neoplasms and non-neoplastic causes account for the 
majority of excess deaths long term.1 2 5
Treatment intensity has typically decreased more 
recently for children with a diagnosis of neoplasms with 
relatively good prognosis in order to prevent premature 
morbidity and mortality from treatment related side 
effects; conversely, treatment has intensified for neo-
plasms with poor prognoses in order to improve sur-
vival. Few studies have addressed late mortality in 
relation to treatment period,3 4 7-9 and those that have 
were restricted by narrow treatment time spans, insuffi-
cient person years at risk, and small numbers of deaths, 
which limited statistical power and inhibited detailed 
classification and investigation of cause specific deaths.
Thus, in this study we aimed to address these previ-
ous limitations by investigating the risk of late cause 
WhAT IS AlReAdy knoWn on ThIS TopIC
Survivors of childhood cancer are at an increased risk of death compared with the 
general population
The principal cause of excess mortality in the short term is recurrence or 
progression of the initial cancer, whereas subsequent primary neoplasms and 
non-neoplastic causes account for most excess deaths long term
Few previous studies have addressed late mortality in relation to treatment period, 
and those that have were restricted by narrow treatment periods, insufficient 
person years at risk, and small numbers of deaths, which limited statistical power 
and inhibited detailed classification and investigation of cause specific deaths
WhAT ThIS STudy AddS
Among survivors of childhood cancer aged at least 60 years, 31% and 37% of excess 
numbers of deaths observed were due to subsequent primary neoplasms and 
circulatory conditions, respectively
The net effects of changes in cancer treatments, and surveillance and management 
for late effects, over the period 1940 to 2006 is to reduce the excess number of 
deaths from both recurrence or progression and non-neoplastic causes among 
those treated more recently
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specific mortality after treatment across almost seven 
decades (1940-2006) within the recently extended Brit-
ish Childhood Cancer Survivor Study (BCCSS). The 
BCCSS now includes 34 489 five year survivors of child-
hood cancer, which is 6056, 7846, and 14 006 more five 
year survivors than that included in the Childhood 
 Cancer Survivor Study (CCSS),7  Surveillance, Epidemiol-
ogy and End Results Program (SEER),8  and Nordic coun-
tries,3 respectively. Our study also included 1496, 1662, 
and 2407 more deaths than that reported by these same 
studies, respectively. Owing to these strengths, we inves-
tigated the impact of factors related to treatment period 
on the risk of specific causes of death and the pattern of 
excess deaths among survivors aged more than 50 years.
Methods
british Childhood Cancer survivor study
The BCCSS is a population based cohort that comprises 
34 489 five year survivors of childhood cancer with a 
diagnosis under the age of 15 years from 1940 to 2006 in 
Britain. The cohort was ascertained by using the 
National Registry of Childhood Tumours, which has an 
approximately 99% ascertainment rate.10 The study is 
maintained at the Centre of Childhood Cancer Survivor 
Studies and additional details on the study and its 
objectives can be found at www.bccss.bham.ac.uk. Eth-
ical approval for the study was obtained from the 
National Research Ethics Service, and the Confidential-
ity Advisory Group consented to processing identified 
data without individual patient consent.
Death ascertainment
To ascertain each survivor’s vital and emigration status, 
the entire BCCSS cohort was linked by the Health and 
Social Care Information Centre (England and Wales) 
and National Health Service Central Register (Scotland) 
to their NHS registration systems using the survivor’s 
NHS number, first name, middle initial, current sur-
name, and date of birth; for survivors who were not 
electronically matched, manual matching was then 
undertaken through collaboration with the Health and 
Social Care Information Centre and NHS Central Regis-
ter. This linkage provided the death certificate and 
underlying cause of death, as coded by the Office for 
National Statistics (England and Wales) and National 
Records of Scotland (Scotland), using the relevant Inter-
national Classification of Diseases in use at date of 
death. We then classified the underlying cause of death, 
as coded on the death certificate, using the principal 
sections of the relevant revision of the International 
Classification of Diseases. However, as it was possible 
that a death from cancer could be due to a recurrence or 
progression of the original childhood cancer or a subse-
quent primary neoplasm, we (MMF, RCR, DLW, and 
MMH) reviewed all deaths due to neoplastic causes to 
determine the appropriate neoplastic specific cause of 
death (either recurrence or progression or subsequent 
primary neoplasm); death certificates, medical notes, 
and autopsy reports were utilised in the review and if 
uncertainty remained we attributed the cause of death 
to recurrence or progression. Follow-up for mortality 
commenced at the date of five year survival and contin-
ued until the first occurrence of emigration, death, or 28 
February 2014.
statistical analyses
Using standard cohort techniques, we calculated stan-
dardised mortality ratios and absolute excess risks.11  The 
standardised mortality ratio was defined as the number 
of observed deaths divided by the expected number of 
deaths. The absolute excess risk was defined as the 
observed minus the expected number of deaths divided 
by person years at risk multiplied by 10 000. We calcu-
lated expected numbers by multiplying the person years 
for each sex, age (five year bands), and calendar year 
(one year bands) specific stratum by the corresponding 
mortality rate for the general population and then sum-
ming the expected numbers across the strata.11 12  As a 
principal objective of this study was to assess trends in 
excess mortality with treatment period, we fitted univari-
able and multivariable Poisson regression models, where 
standardised mortality ratios and absolute excess risks 
were calculated from the univariate model and excess 
mortality ratios, which are essentially the ratio of abso-
lute excess risks adjusting for other factors, were calcu-
lated from the multivariable model. We used the 
multivariable model to evaluate the simultaneous effect 
of several factors: sex, type of first primary neoplasm, 
age at cancer diagnosis, treatment period, attained age, 
and years of follow-up. Because of strong collinearity, we 
did not include attained age and years of follow-up in the 
same Poisson regression model. To test for heterogeneity 
or trend, we used likelihood ratio tests within Poisson 
regression models. All analyses were completed using 
Stata 13.1 statistical software,13 where the criterion for 
statistical significance was a two sided P<0.05.
Patient involvement
Two patient representatives attend the BCCSS Steering 
Group meetings. Survivors overall showed their over-
whelming support for the study by returning 10 488 
questionnaires, representing 80% of those sent. Almost 
all of the survivors who completed the questionnaire 
requested to receive study newsletters, the means by 
which we inform them of the findings of the research.
Results
study characteristics
The cohort was followed up for a total of 620 753 person 
years, with a median follow-up of 15.2 (range 0.0-68.7) 
years from five year survival and to a median attained 
age of 27.0 (range 5.5-85.6) years (table 1). When we 
assessed the cohort by follow-up, 31 582 person years 
were observed beyond 40 years; by attained age, 21 696 
person years were observed beyond 50 years. Overall, 
4475 people (13.0%) had died by the study exit date. 
Supplementary eTable 1 reports the distribution of the 
cohort characteristics by treatment period.
all causes of death
Overall, survivors experienced 9.1 times (95% confi-
dence interval 8.9 to 9.4) more deaths than that expected 
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from the general population, which corresponded to 
64.2 (95% confidence interval 62.1 to 66.3) excess deaths 
per 10 000 person years (table 2 ). With regards to abso-
lute excess risks, over 50 excess deaths per 10 000 per-
son years were observed for survivors of central nervous 
system (CNS) neoplasms (excluding primitive neuroec-
todermal tumour), CNS primitive neuroectodermal 
tumour, leukaemia (excluding acute myeloid leukae-
mia), acute myeloid leukaemia, Hodgkin’s lymphoma, 
heritable retinoblastoma, bone sarcoma, and soft tissue 
sarcoma (table 3 ). When assessed by treatment period, 
the absolute excess risks decreased significantly (P for 
trend <0.01) among those with a more recent diagnosis. 
After adjusting for sex, type of first primary neoplasm, 
age at diagnosis, and attained age, those with a diagno-
sis of cancer from 1990 to 2006 experienced 30% 
(excess mortality ratio 0.3, 95% confidence interval 0.3 
to 0.4) of the excess deaths observed among those with 
a diagnosis before 1970 (table 4).
When treatment period was further assessed, a statis-
tically significant decline in excess mortality among 
those with a more recent diagnosis was observed for 
several types of first primary neoplasms, after adjusting 
for sex, age at diagnosis, and attained age: CNS neo-
plasms (excluding primitive neuroectodermal tumour) 
(P for trend <0.01), CNS primitive neuroectodermal 
tumour (P for trend <0.01), leukaemia (excluding acute 
myeloid leukaemia) (P for trend <0.01), acute myeloid 
leukaemia (P for trend 0.03), Hodgkin’s lymphoma (P 
for trend <0.01), non-Hodgkin’s lymphoma (P for trend 
0.03), heritable retinoblastoma (P for trend 0.04), and 
other types of first primary neoplasms (P for trend 0.01, 
table 5). The largest declines in excess all cause mortal-
ity were observed among survivors of leukaemia 
(excluding acute myeloid leukaemia) and Hodgkin’s 
lymphoma, as survivors with a diagnosis from 1990 to 
2006 experienced 10% (both excess mortality ratios 0.1, 
95% confidence interval 0.1 to 0.1) of the number of 
excess deaths observed among survivors with a diagno-
sis before 1970. Survivors of CNS neoplasms (excluding 
primitive neuroectodermal tumour), CNS primitive neu-
roectodermal tumour, non-Hodgkin’s lymphoma, her-
itable retinoblastoma, and other types of first primary 
neoplasms also showed substantial declines in excess 
mortality, with at least a 50% (all excess mortality ratios 
≤0.5) decline in excess all cause mortality among survi-
vors with a diagnosis from 1990 to 2006 compared with 
survivors with a diagnosis before 1970.
Cause specific mortality
The standardised mortality ratio was significantly 
increased for all causes of death, except for deaths due 
to a mental disorder (table 2 ). Recurrence or progres-
sion of the original tumour was the leading cause of 
death, accounting for 65.9% of the excess deaths among 
survivors. Subsequent primary neoplasms and circula-
tory causes of death were the next largest contributors 
to excess deaths, accounting for 16.8% and 5.6% of the 
excess, respectively. As attained age increased, subse-
quent primary neoplasms and non-neoplastic causes 
increasingly accounted for excess mortality, at 41.1% 
and 47.8% of excess deaths among survivors aged 50-59, 
respectively, and 31.4% and 53.0% of excess deaths 
among survivors aged 60 or more, respectively (table 6). 
In particular, the main contributor to excess mortality 
with increased attained age was circulatory causes, 
which accounted for 36.8% of the total excess mortality 
and 69.4% of the excess non-neoplastic mortality 
among those aged 60 years or more.
Further investigations into cause specific mortality 
were conducted for each cause of death, with at least 
150 observed events. These were recurrence or progres-
sion, subsequent primary neoplasms, non-neoplastic 
causes overall, circulatory causes, respiratory causes, 
and external causes.
table 1 | Cohort characteristics of the british Childhood Cancer survivor study
Characteristics Dead (%) alive (%) total no
Overall 4475 (13.0) 30 014 (87.0) 34 489
Male 2629 (13.9) 16 310 (86.1) 18 939
Female 1846 (11.9) 13 704 (88.1) 15 550
First primary neoplasm type:
 CNS (excluding PNET) 1334 (19.1) 5636 (80.9) 6970
 CNS PNET 340 (28.4) 858 (71.6) 1198
 Leukaemia (excluding AML) 1104 (11.6) 8398 (88.4) 9493
 AML 82 (8.4) 899 (91.6) 981
 Hodgkin’s lymphoma 331 (14.8) 1903 (85.2) 2234
 Non-Hodgkin’s lymphoma 131 (8.5) 1418 (91.5) 1549
 Neuroblastoma 144 (9.4) 1391 (90.6) 1535
 Non-heritable retinoblastoma 31 (3.1) 975 (96.9) 1006
 Heritable retinoblastoma 138 (18.4) 612 (81.6) 750
 Wilms’s tumour 184 (7.7) 2204 (92.3) 1388
 Bone sarcoma 198 (16.6) 997 (83.4) 1195
 Soft tissue sarcoma 253 (11.8) 1894 (88.2) 2147
 Other 205 (6.7) 2838 (93.3) 3043
Age at diagnosis (years):
 0-4 1662 (10.6) 14 035 (89.4) 15 697
 5-9 1351 (14.6) 7913 (85.4) 9264
 10-14 1462 (15.3) 8066 (84.7) 9528
Treatment period:
 1940-69 1329 (35.5) 2417 (64.5) 3746
 1970-79 1247 (23.2) 4132 (76.8) 5379
 1980-89 942 (13.2) 6205 (86.8) 7147
 1990-99 703 (7.0) 9328 (93.0) 10 031
 2000-06 254 (3.1) 7932 (96.9) 8186
Years from diagnosis:
 Median (range) 6.1 (0.0-65.3) 16.2 (0.0-68.7) 15.2 (0.0-68.7)
 5-9 2054 (37.9) 3368 (62.2) 5422
 10-19 1060 (9.1) 10 561 (90.9) 11 621
 20-29 548 (6.9) 7352 (93.1) 7900
 30-39 417 (7.7) 5026 (92.3) 5443
 40-49 277 (9.9) 2529 (90.1) 2806
 50-59 103 (8.9) 1052 (91.1) 1155
 ≥60 16 (11.3) 126 (88.7) 142
Attained age (years) at exit:
 Median (range) 20.0 (5.5-79.8) 27.9 (5.8-85.6) 27.0 (5.5-85.6)
 5-9 416 (48.9) 435 (51.1) 851
 10-19 1831 (21.7) 6614 (78.3) 8445
 20-29 1003 (9.4) 9730 (90.7) 10 733
 30-39 535 (8.1) 6083 (91.9) 6618
 40-49 364 (7.5) 4486 (92.5) 4850
 50-59 238 (11.4) 1859 (88.7) 2097
 ≥60 88 (9.8) 807 (90.2) 895
CNS=central nervous system; PNET=primitive neuroectodermal tumour; AML=acute myeloid leukaemia.
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Deaths due to recurrence or progression
Among 3421 deaths due to cancer, 2626 (76.8%) were 
attributed to recurrence or progression of the original 
cancer, which equated to 42.3 (95% confidence interval 
40.7 to 43.9) excess deaths per 10 000 person years 
(table 2 ). All types of first primary neoplasms, except 
non-heritable retinoblastoma, were found to have 
excess deaths due to recurrence or progression, but 
noticeable excesses were observed for survivors of CNS 
neoplasms (excluding primitive neuroectodermal 
tumour) (absolute excess risk 64.8), CNS primitive neu-
roectodermal tumour (115.0), leukaemia (excluding 
acute myeloid leukaemia) (57.1), and bone sarcoma 
(61.9), where more than 50 excess deaths per 10 000 
person years were observed (table 3 ). With regards to 
treatment period, the absolute excess risk significantly 
decreased among those treated more recently (P for 
trend <0.01) (table 4); compared with survivors with a 
diagnosis before 1970, those with a diagnosis from 1990 
to 2006 experienced 30% (excess mortality ratio 0.3, 
95% confidence interval 0.2 to 0.3) of the excess deaths 
due to recurrence or progression, after adjusting for sex, 
type of first primary neoplasm, age at diagnosis, and 
attained age.
When treatment period was assessed by type of first 
primary neoplasm, survivors of CNS neoplasms 
(excluding primitive neuroectodermal tumour) (P for 
trend <0.01), CNS primitive neuroectodermal tumour (P 
for trend <0.01), leukaemia (excluding acute myeloid 
leukaemia) (P for trend <0.01), acute myeloid leukae-
mia (P for trend 0.02), Hodgkin’s lymphoma (P for 
trend <0.01), non-Hodgkin’s lymphoma (P for trend 
0.02), and other types of first primary neoplasm (P for 
trend <0.01) were found to have significantly fewer 
excess numbers of deaths among those with a most 
recent diagnosis, after adjustment (table 5). The stron-
gest decline in the excess number of deaths due to 
recurrence or progression was observed for survivors of 
leukaemia ( excluding acute myeloid leukaemia) and 
Hodgkin’s lymphoma, as survivors with a diagnosis 
from 1990 to 2006 experienced 10% (both excess mor-
tality ratios 0.1, 95% confidence interval 0.0 to 0.1) of 
the excess number of deaths due to recurrence or pro-
gression observed among those with a diagnosis before 
1970; for both types of first primary neoplasm the 
strongest decline in excess number of deaths due to 
recurrence or progression was observed from the treat-
ment period before 1970 to the treatment period of 
1970-79. Survivors of CNS neoplasms (excluding primi-
tive neuroectodermal tumour) with a diagnosis from 
1990 to 2006 experienced 30% (excess mortality ratio 
0.3, 95% confidence interval 0.3 to 0.4) of the excess 
number of deaths due to recurrence or progression 
observed among those with a diagnosis before 1970; 
the corresponding percentage for survivors of CNS 
primitive neuroectodermal tumour (0.4, 0.2 to 0.5), 
acute myeloid leukaemia (0.4, 0.0 to 2.7), and non-Hod-
gkin’s lymphoma (0.4, 0.2 to 0.9) was 40%.
Deaths due to subsequent primary neoplasms
Survivors of childhood cancer were 6.3 times (95% con-
fidence interval 5.8 to 6.7) more at risk of death due to a 
subsequent primary neoplasm than expected in the 
general population (table 2 ). Survivors of CNS primitive 
neuroectodermal tumour and heritable retinoblastoma 
had the greatest risk of death related to subsequent pri-
mary neoplasms, with standardised mortality ratios of 
21.6 (95% confidence interval 16.9 to 27.2) and 21.0 (17.0 
to 25.5), respectively (table 3 ). After adjusting for sex, 
type of first primary neoplasm, age at diagnosis, and 
attained age, there was no statistical evidence of an 
overall decline in the excess numbers of deaths from 
subsequent primary neoplasms with more recent treat-
ment period (P for trend 0.10, table 4).
After adjustment, survivors of Wilms’s tumour (P for 
trend 0.02) with a more recent diagnosis experienced a 
lower number of excess deaths due to subsequent pri-
mary neoplasms (table 5). Conversely, among survivors 
of soft tissue sarcoma, the excess number of deaths 
from subsequent primary neoplasms increased among 
those with a more recent diagnosis (P for trend 0.04); 
more specifically, survivors of soft tissue sarcoma diag-
nosed during 1970-79, 1980-89, and 1990-2006 experi-
enced 7.3 times (95% confidence interval 1.7 to 31.6), 4.7 
times, (0.9 to 23.7), and 6.8 times (1.3 to 35.1) more 
excess deaths due to subsequent primary neoplasms 
than those with a diagnosis before 1970, respectively. A 
significant positive or negative trend for excess number 
of deaths related to subsequent primary neoplasms was 
not observed with treatment period for any other type of 
first primary neoplasm (all P for trend >0.05).
Deaths due to non-neoplastic causes
Survivors of childhood cancer were 2.9 times (95% con-
fidence interval 2.7 to 3.1) more likely to die from a 
non-neoplastic cause of death than expected from the 
general population, which equated to 11.1 (95% confi-
dence interval 10.1 to 12.1) excess deaths due to non-neo-
plastic causes per 10 000 person years (table 2 ). 
table 2 | Observed and expected deaths, standardised mortality ratio, and absolute 
excess risk of specific causes of death
Causes of death Observed/expected sMr (95% Ci)
absolute excess  
risk (95% Ci)
All causes 4475/490.9 9.1 (8.9 to 9.4) 64.2 (62.1 to 66.3)
Recurrence or progression 2626/0.0 NA 42.3 (40.7 to 43.9)
Subsequent primary neoplasm 795/126.9 6.3 (5.8 to 6.7) 10.8 (9.9 to 11.7)
Non-neoplastic 1054/364.0 2.9 (2.7 to 3.1) 11.1 (10.1 to 12.1)
 Circulatory 300/78.0 3.8 (3.4 to 4.3) 3.6 (3.0 to 4.1)
 Respiratory 164/24.2 6.8 (5.8 to 7.9) 2.3 (1.8 to 2.7)
 Nervous 98/23.0 4.3 (3.5 to 5.2) 1.2 (0.9 to 1.5)
 Infection 67/9.1 7.4 (5.7 to 9.4) 0.9 (0.7 to 1.2)
 Digestive 63/30.6 2.1 (1.6 to 2.6) 0.5 (0.3 to 0.8)
 Perinatal 42/9.5 4.4 (3.2 to 6.0) 0.5 (0.3 to 0.7)
 Endocrine 32/10.5 3.1 (2.1 to 4.3) 0.3 (0.2 to 0.5)
 Genitourinary 30/3.3 9.2 (6.2 to 13.2) 0.4 (0.3 to 0.6)
 Musculoskeletal 18/3.0 6.0 (3.5 to 9.4) 0.2 (0.1 to 0.4)
 Mental 15/13.3 1.1 (0.6 to 1.9) 0.0 (−0.1 to 0.1)
 Blood 16/2.1 7.5 (4.3 to 12.2) 0.2 (0.1 to 0.3)
 External* 188/151.7 1.2 (1.1 to 1.4) 0.6 (0.2 to 1.0)
 Other 21/5.7 3.7 (2.3 to 5.7) 0.2 (0.1 to 0.4)
SMR=standardised mortality ratio; NA=not applicable.
*Includes deaths due to transportation accidents, falls, drowning, fire, suicide, etc.
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table 5 | excess mortality ratios for all, recurrence or progression, subsequent primary neoplasm, and non-neoplastic causes of death, by first primary 
neoplastic type and treatment period
First primary neoplasm by 
treatment period
all causes recurrence or progression
subsequent primary 
neoplasms non-neoplastic
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
CNS (excluding PNET):
 <1970 506/62.6 1.0 (ref) 275/0.0 1.0 (ref) 53/22.6 1.0 (ref) 178/40.0 1.0 (ref)
 1970-79 335/27.2 0.8 (0.7 to 0.9) 193/0.0 0.7 (0.6 to 0.8) 41/6.2 1.6 (0.9 to 3.0) 101/20.9 1.0 (0.7 to 1.4)
 1980-89 252/15.0 0.7(0.6 to 0.8) 165/0.0 0.6(0.5 to 0.7) 27/2.4 1.6(0.9 to 3.2) 60/12.6 0.9(0.6 to 1.3)
 1990-2006 241/10.8 0.4(0.3 to 0.5) 175/0.0 0.3(0.3 to 0.4) 27/1.5 1.5(0.8 to 3.1) 39/9.3 0.5(0.3 to 0.9)
P for trend* <0.01 <0.01 0.24 0.02
CNS PNET:
 <1970 106/6.6 1.0 (ref) 61/0.0 1.0 (ref) 27/2.1 1.0 (ref) 18/4.6 1.0 (ref)
 1970-79 76/3.5 0.7(0.5 to 1.0) 39/0.0 0.5(0.4 to 0.8) 18/0.7 1.0(0.5 to 2.0) 19/2.8 1.9(0.7 to 4.8)
 1980-89 67/2.7 0.6(0.4 to 0.8) 50/0.0 0.6(0.4 to 0.8) 8/0.4 0.5(0.2 to 1.1) 9/2.3 1.2(0.4 to 4.0)
 1990-2006 91/1.8 0.5(0.3 to 0.6) 65/0.0 0.4(0.2 to 0.5) 19/0.2 0.9(0.4 to 2.0) 7/1.6 0.8(0.2 to 2.8)
P for trend* <0.01 <0.01 0.54 0.69
Leukaemia (excluding AML):
 <1970 98/4.1 1.0 (ref) 94/0.0 1.0 (ref) 1/1.3 1.0 (ref) 3/2.8 1.0 (ref)
 1970-79 414/29.2 0.3(0.2 to 0.4) 309/0.0 0.2(0.2 to 0.3) 50/5.9 8.5(0.1 to 503.4) 55/23.3 NP
 1980-89 289/23.1 0.1(0.1 to 0.2) 207/0.0 0.1(0.1 to 0.1) 32/3.4 5.1(0.1 to 309.5) 50/19.6 NP
 1990-2006 303/14.8 0.1(0.1 to 0.1) 220/0.0 0.1(0.0 to 0.1) 43/2.1 6.7(0.1 to 401.6) 40/12.7 NP
P for trend* <0.01 <0.01 0.71 0.10
AML:
 <1970 2/0.6 1.0 (ref) 1/0.0 1.0 (ref) 1/0.2 1.0 (ref) 0/0.4 1.0 (ref)
 1970-79 14/1.6 1.8(0.3 to 10.5) 7/0.0 0.8(0.1 to 6.9) 4/0.3 2.1(0.1 to 40.5) 3/1.3 NP
 1980-89 36/2.0 2.3(0.4 to 13.5) 15/0.0 0.7(0.1 to 5.2) 7/0.3 2.7(0.1 to 58.4) 14/1.7 NP
 1990-2006 30/2.0 0.9(0.1 to 5.3) 21/0.0 0.4(0.0 to 2.7) 0/0.3 NP 9/1.7 NP
P for trend* 0.03 0.02 0.13 0.24
Hodgkin’s lymphoma:
 <1970 156/19.2 1.0 (ref) 87/0.0 1.0 (ref) 33/6.5 1.0 (ref) 36/12.8 1.0 (ref)
 1970-79 105/14.8 0.4(0.3 to 0.6) 40/0.0 0.2(0.2 to 0.4) 32/3.2 1.4(0.7 to 2.7) 33/11.6 0.8(0.3 to 1.8)
 1980-89 42/9.1 0.2(0.1 to 0.2) 19/0.0 0.1(0.1 to 0.2) 10/1.4 0.6(0.3 to 1.7) 13/7.7 0.4(0.1 to 1.2)
 1990-2006 28/4.2 0.1(0.1 to 0.1) 14/0.0 0.1(0.0 to 0.1) 5/0.5 0.6(0.2 to 2.0) 9/3.7 0.3(0.1 to 1.1)
P for trend* <0.01 <0.01 0.27 0.03
Non-Hodgkin’s lymphoma:
 <1970 46/15.7 1.0 (ref) 12/0.0 1.0 (ref) 12/5.6 1.0 (ref) 22/10.2 1.0 (ref)
 1970-79 27/6.5 0.9(0.5 to 1.7) 11/0.0 0.9(0.4 to 2.0) 9/1.3 4.1(0.7 to 23.9) 7/5.2 0.5(0.1 to 2.2)
 1980-89 31/6.3 0.6(0.3 to 1.2) 11/0.0 0.5(0.2 to 1.1) 5/0.9 1.8(0.2 to 13.7) 15/5.5 0.7(0.2 to 3.0)
 1990-2006 27/3.3 0.5(0.3 to 1.0) 14/0.0 0.4(0.2 to 0.9) 5/0.4 1.6(0.2 to 11.9) 8/2.9 0.3(0.0 to 2.7)
P for trend* 0.03 0.02 0.92 0.33
Neuroblastoma:
 <1970 49/10.1 1.0 (ref) 18/0.0 1.0 (ref) 11/3.1 1.0 (ref) 20/7.1 1.0 (ref)
 1970-79 23/2.7 1.1(0.6 to 1.9) 13/0.0 1.1(0.6 to 2.4) 5/0.5 1.3(0.4 to 4.9) 5/2.3 0.8(0.2 to 3.0)
 1980-89 29/2.5 0.8(0.5 to 1.5) 17/0.0 0.8(0.4 to 1.6) 4/0.4 1.0(0.2 to 4.4) 8/2.1 0.7(0.2 to 2.8)
 1990-2006 43/1.5 0.8(0.5 to 1.4) 37/0.0 1.0(0.5 to 1.7) 2/0.3 0.6(0.1 to 4.1) 4/1.2 0.3(0.1 to 2.1)
P for trend* 0.33 0.76 0.70 0.25
Non-heritable retinoblastoma:
 <1970 19/17.0 1.0 (ref) 0/0.0 1.0 (ref) 13/5.8 1.0 (ref) 6/11.2 1.0 (ref)
 1970-79 9/4.1 9.0(0.1 to 1357.2) 0/0.0 1.0 1/0.7 0.4(0.0 to 8.2) 8/3.4 NP
 1980-89 2/1.4 13.2(0.0 to 6321.2) 0/0.0 1.0 1/0.2 2.0(0.1 to 50.7) 1/1.2 NP
 1990-2006 1/0.8 NP 0/0.0 1.0 0/0.1 NP 1/0.6 NP
P for trend* 0.92 NA 0.62 0.76
Heritable retinoblastoma:
 <1970 96/13.2 1.0 (ref) 11/0.0 1.0 (ref) 71/4.1 1.0 (ref) 14/9.1 1.0 (ref)
 1970-79 21/2.3 0.9(0.5 to 1.5) 3/0.0 0.7(0.2 to 2.5) 15/0.4 0.9(0.5 to 1.7) 3/1.9 NP
 1980-89 17/1.0 1.0(0.6 to 1.9) 5/0.0 1.2(0.4 to 3.7) 11/0.1 1.0(0.5 to 2.0) 1/0.9 2.5(0.1 to 61.7)
 1990-2006 4/0.4 0.3(0.1 to 0.8) 2/0.0 0.4(0.1 to 1.9) 2/0.1 0.2(0.0 to 1.0) 0/0.3 NP
P for trend* 0.04 0.42 0.09 1.00
Wilms’s tumour:
 <1970 75/16.6 1.0 (ref) 11/0.0 1.0 (ref) 29/5.2 1.0 (ref) 35/11.4 1.0 (ref)
 1970-79 65/10.0 1.2(0.8 to 1.9) 19/0.0 1.2(0.6 to 2.5) 17/1.8 0.9(0.4 to 2.0) 29/8.2 1.6(0.7 to 3.5)
(Continued )
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Survivors of acute myeloid leukaemia, CNS primitive 
neuroectodermal tumour, and CNS neoplasms (exclud-
ing primitive neuroectodermal tumour) were at greatest 
risk of death due to non-neoplastic causes, with stan-
dardised mortality ratios of 5.1 (95% confidence interval 
3.3 to 7.5), 4.7 (3.5 to 6.2), and 4.6 (4.1 to 5.0), respectively 
(table 3 ). The number of excess deaths due to non-neo-
plastic causes among survivors was also observed to 
decrease in more recent treatment periods (P for trend 
<0.01), after adjusting for sex, type of first primary neo-
plasm, age at diagnosis, and attained age (table 4); sur-
vivors with a diagnosis from 1990 to 2006 experienced 
60% (excess mortality ratio 0.6, 95%confidence interval 
0.4 to 0.8) of the excess number of deaths due to 
non-neoplastic causes observed among survivors with 
a diagnosis before 1970.
When treatment period was further assessed by type 
of first primary neoplasm, only survivors of CNS neo-
plasms (excluding primitive neuroectodermal tumour) (P 
for trend 0.02) and Hodgkin’s lymphoma (P for 
trend=0.03) were found to have a significant decrease in 
excess mortality due to non-neoplastic causes among 
those treated more recently, after adjustment (table 5). 
Survivors of CNS neoplasms (excluding primitive neuro-
ectodermal tumour) with a diagnosis from 1990 to 2006 
experienced 50% (excess mortality ratio 0.5, 95% confi-
dence interval 0.3 to 0.9) of the excess number of deaths 
due to non-neoplastic causes observed among survivors 
with a diagnosis before 1970, whereas the corresponding 
percentage for survivors of Hodgkin’s lymphoma was 
30% (0.3, 0.1 to 1.1).
Deaths due to circulatory causes
Circulatory causes accounted for the largest number of 
deaths due to non-neoplastic causes, with 300 observed 
events (table 2 ). Survivors were 3.8 times (95% confi-
dence interval 3.4 to 4.3) more at risk of death due to 
circulatory causes than expected from the general pop-
ulation, which equated to 3.6 (95% confidence interval 
3.0 to 4.1) excess deaths due to circulatory causes per 
10 000 person years. The risk of death due to circulatory 
causes was substantially increased (standardised mor-
tality ratio ≥5) for survivors of acute myeloid leukaemia 
(16.6), CNS primitive neuroectodermal tumour (6.8), 
Wilms’s tumour (5.8), and Hodgkin’s lymphoma (5.0) 
(table 7 ). In the multivariable Poisson model there was 
no statistical evidence of a decline in excess numbers of 
death from circulatory causes with more recent treat-
ment period (P for trend 0.19), after adjusting for sex, 
type of first primary neoplasm, age at diagnosis, and 
attained age (table 8).
Death due to respiratory causes
Deaths due to respiratory causes occurred 6.8 times 
(95% confidence interval 5.8 to 7.9) more than that 
expected from the general population (table 2 ). A sub-
stantial excess risk (standardised mortality ratio ≥5) 
was observed among survivors of CNS primitive neuro-
ectodermal tumour (22.6), acute myeloid leukaemia 
(12.6), CNS (excluding primitive neuroectodermal 
tumour) (11.9), leukaemia (excluding acute myeloid leu-
kaemia) (8.5), neuroblastoma (7.2), and soft tissue sar-
coma (5.4) (table 7 ). After adjusting for sex, type of first 
table 5 | excess mortality ratios for all, recurrence or progression, subsequent primary neoplasm, and non-neoplastic causes of death, by first primary 
neoplastic type and treatment period
First primary neoplasm by 
treatment period
all causes recurrence or progression
subsequent primary 
neoplasms non-neoplastic
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
Observed/
expected eMr (95% Ci)
 1980-89 29/4.9 0.8(0.4 to 1.4) 10/0.0 0.6(0.3 to 1.5) 3/0.7 0.2(0.0 to 1.3) 16/4.2 2.0(0.7 to 5.5)
 1990-2006 15/2.3 0.5(0.2 to 1.0) 12/0.0 0.6(0.3 to 1.4) 0/0.4 NP 3/1.9 NP
P for trend* 0.05 0.08 0.02 0.69
Bone sarcoma:
 <1970 48/13.2 1.0 (ref) 25/0.0 1.0 (ref) 13/5.2 1.0 (ref) 10/8.0 1.0 (ref)
 1970-79 41/5.3 0.9(0.5 to 1.4) 23/0.0 0.8(0.4 to 1.4) 10/1.3 1.3(0.4 to 4.3) 8/4.0 0.2(0.0 to 
1349.8)
 1980-89 44/3.9 0.8(0.5 to 1.3) 29/0.0 0.7(0.4 to 1.2) 11/0.7 1.6(0.5 to 5.1) 4/3.2 NP
 1990-2006 65/2.3 0.8(0.5 to 1.2) 58/0.0 0.8(0.5 to 1.3) 3/0.3 0.4(0.1 to 1.9) 4/2.0 1.1(0.1 to 9.6)
P for trend* 0.35 0.59 0.39 0.75
Soft tissue sarcoma:
 <1970 60/22.9 1.0 (ref) 26/0.0 1.0 (ref) 13/8.0 1.0 (ref) 21/14.8 1.0 (ref)
 1970-79 66/7.3 1.7(1.1 to 2.7) 34/0.0 1.4(0.8 to 2.3) 17/1.5 7.3(1.7 to 31.6) 15/5.8 3.0(0.4 to 24.0)
 1980-89 53/5.6 1.1(0.7 to 1.7) 35/0.0 0.9(0.6 to 1.6) 9/0.9 4.7(0.9 to 23.7) 9/4.7 0.8(0.1 to 10.5)
 1990-2006 74/3.4 1.1(0.7 to 1.7) 54/0.0 0.9(0.5 to 1.4) 11/0.5 6.8(1.3 to 35.1) 9/3.0 2.2(0.3 to 19.6)
P for trend* 0.50 0.20 0.04 0.66
Other:
 <1970 68/26.3 1.0 (ref) 17/0.0 1.0 (ref) 18/10.1 1.0 (ref) 33/16.2 1.0 (ref)
 1970-79 51/10.5 0.9(0.6 to 1.5) 17/0.0 0.9(0.4 to 1.7) 21/2.9 1.8(0.7 to 4.4) 13/7.5 0.4(0.1 to 1.7)
 1980-89 51/7.5 0.8(0.5 to 1.3) 28/0.0 1.1(0.6 to 2.1) 10/1.4 0.8(0.3 to 2.2) 13/6.1 0.4(0.1 to 1.7)
 1990-2006 35/5.3 0.3(0.2 to 0.6) 17/0.0 0.3(0.2 to 0.7) 5/0.7 0.4(0.1 to 1.3) 13/4.5 0.6(0.2 to 2.2)
P for trend* <0.01 <0.01 0.06 0.42
EMR=excess mortality ratio; CNS=central nervous system; PNET=primitive neuroectodermal tumour; AML=acute myeloid leukaemia; NA=not applicable; NP=not possible to reliably calculate 
owing to small numbers.
*P for trend determined from multivariable Poisson model adjusted for sex, age at diagnosis, treatment period, and attained age. 
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primary neoplasm, age at diagnosis, and attained age, 
a statistically significant decline (P for trend 0.01) in 
excess number of deaths was observed among those 
treated more recently (table 8); compared with survi-
vors who received a diagnosis before 1970, survivors 
who received a diagnosis from 1990 to 2006 experi-
enced 40% (excess mortality ratio 0.4, 95% confidence 
interval 0.2 to 0.8) of the excess number of deaths due to 
respiratory causes.
Deaths due to external causes
Survivors of childhood cancer had a slight increased 
risk of death due to external causes compared with that 
expected from the general population, with a stan-
dardised mortality ratio of 1.2 (95% confidence interval 
1.1 to 1.4) (table 2 ). Only survivors of CNS neoplasms 
(excluding primitive neuroectodermal tumour) (2.0, 1.5 
to 2.6) and neuroblastoma (2.2, 1.1 to 3.9) had a signifi-
cant increased risk compared with that expected from 
the general population (table 7 ). With regards to treat-
ment period, the number of excess deaths due to exter-
nal causes significantly declined (P for trend <0.01) 
among those treated more recently, with those treated 
from 1990 to 2006 having no observed excess risk, after 
adjusting for sex, type of first primary neoplasm, age at 
diagnosis, and attained age (table 8).
discussion 
This study of late mortality after childhood cancer 
within a cohort of 34 489 five year survivors, among 
whom 4475 deaths were observed, provides an opportu-
nity to investigate the impact of treatment period (1940-
2006) on the risk of specific causes of death and the 
pattern of excess deaths among survivors aged at least 
50 years. Previously we have reported the risk of cause 
specific death after childhood cancer within the same 
cohort.2  However, this updated analysis includes an 
additional 16 509 five year survivors, and adds a further 
1434 deaths and 250 728 person years, thus exceeding 
considerably the numbers available in our previous 
study and comparable studies by the CCSS,7  SEER,8 
and Nordic countries.3 Our methodological focus is dif-
ferent to these previous studies, as they concentrated 
on either cumulative risks, which ignore expected mor-
tality when assessing differences in curves, or stan-
dardised mortality ratios, which being a measure of 
relative risk relate to a baseline risk that is often unclear. 
We concentrated on the absolute excess risk, which is 
an excess number of observed deaths beyond those 
expected from the general population, and so is directly 
interpretable in terms of adverse health impact on sur-
vivors.
Our findings indicate that the net effect of more mod-
ern cancer treatment, and increased surveillance and 
treatment of late effects, which were more commonly 
available among survivors treated more recently, was to 
reduce excess mortality. The number of excess deaths 
from all causes declined among those treated more 
recently, in that those treated from 1990 to 2006 had 
30% of the excess number experienced by those treated 
before 1970. The corresponding percentages for the ta
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number of excess deaths from recurrence or progres-
sion and non-neoplastic causes were 30% and 60%, 
respectively.
Previous literature has suggested that late mortality 
was higher in earlier treatment periods (before 1970) 
than in more recent times (1970 to 2016).14-17  Three pre-
vious large cohorts from SEER,8  the CCSS,7  and the Nor-
dic countries3  have reported on treatment period effects 
among survivors of childhood cancer, where in all three 
cohorts observed there was a significant decline in 
cumulative mortality from all causes and deaths due to 
recurrence or progression for those with a more recent 
diagnosis. The Nordic countries also reported a statisti-
cally significant decline in deaths due to non-neoplastic 
causes and no treatment period effect for deaths due to 
subsequent primary neoplasms,3  whereas the CCSS 
also reported significant declines for subsequent pri-
mary neoplasms and for cardiac and respiratory 
causes.7  Our findings confirm those of these three stud-
ies, as well as smaller reports that investigated treat-
ment period trends in Scotland4  and Canada,9  as we 
too found a decline in excess mortality for deaths due to 
all causes, recurrence or progression, and non-neoplas-
tic causes. We did not observe a decline in the excess 
numbers of deaths from subsequent primary neoplasms 
or from circulatory causes overall, as reported by the 
CCSS,7 but when we restricted the period of diagnosis 
within the BCCSS cohort from 1970 to 1999 (to match the 
CCSS) there was evidence of a decline in the excess 
number of deaths from both subsequent primary neo-
plasms and circulatory causes among those with a more 
recent diagnosis; the excess number of deaths from 
subsequent primary neoplasm and circulatory causes 
among those with a diagnosis from 1995 to 1999 was 
48% and 21% of those observed among those with a 
diagnosis from 1970 to 1975, respectively.
When we assessed trends in excess deaths with treat-
ment period by first primary diagnosis, most types of 
first primary neoplasm (CNS (excluding primitive neu-
roectodermal tumour), CNS primitive neuroectodermal 
tumour, leukaemia (excluding acute myeloid leukae-
mia), acute myeloid leukaemia, Hodgkin’s lymphoma, 
non-Hodgkin’s lymphoma, heritable retinoblastoma, 
and other first primary neoplasms) experienced signifi-
cantly fewer excess deaths from all causes after treat-
ment from 1990 to 2006 compared with treatment 
before 1970. These findings add to the literature, which 
to date has only identified significant declines with 
treatment period in all cause mortality for survivors of 
leukaemia,3 7 8  Hodgkin’s lymphoma,3 7 8  non-Hodgkin’s 
lymphoma,7 8  rhabdomyosarcoma,8  neuroblastoma,7 
and some CNS cancers.3 7  As observed in SEER,8  CCSS,7 
and the Nordic studies,3  this reduction was largely due 
to decreasing mortality from recurrence or progression 
in those with a more recent diagnosis, and suggests that 
survivors of treatment in more recent periods have more 
durable remissions, or that the treatment for relapse, 
recurrence, or progression of the first primary neoplasm 
has improved more recently. When we assessed deaths 
due to subsequent primary neoplasm for treatment 
period effects, survivors of Wilms’s tumour and soft tis-
sue sarcoma experienced significantly less and signifi-
cantly more excess deaths due to subsequent primary 
neoplasm, respectively, among those with a more recent 
diagnosis. This is inconsistent with the Nordic report, 
as only survivors of CNS cancer were identified as hav-
ing a statistically significant decline in excess deaths 
due to subsequent primary neoplasm with treatment 
period.3  We additionally identified statistically signifi-
cant declines in deaths due to non-neoplastic causes for 
survivors of CNS neoplasms (excluding primitive neuro-
ectodermal tumour) and Hodgkin’s lymphoma. 
Although the Nordic countries also found a statistically 
significant decline in non-neoplastic mortality for sur-
vivors of Hodgkin’s lymphoma, a significant decrease 
was also observed for survivors of leukaemia, which 
was not observed in the current study.3  Potential expla-
nations for the differences observed between studies 
may relate to the number of deaths observed for each 
type of first primary neoplasm in each treatment period, 
age definition of childhood cancer, available follow-up 
time, length of diagnosis period assessed, and differ-
ences in treatment regimens utilised—the last of which 
has been clearly documented for survivors of acute 
myeloid leukaemia.18 19 However, as our study included 
more deaths, longer follow-up, and a wider period of 
diagnosis, there is greater statistical power for detecting 
decreases in cause specific mortality.
This study also assessed late mortality among a 
population of survivors of childhood cancer in their 
sixth and seventh decades of life. Among those aged at 
least 50 years, the percentage of excess deaths due to 
non-neoplastic causes was about 50%, and this is 
likely to be an underestimate for two reasons. Firstly, 
table 8 | excess mortality ratios from univariable and multivariable Poisson models assessing the risk of circulatory, respiratory, and external causes of 
death by treatment period
treatment 
period
Circulatory causes respiratory causes external causes*
Observed/
expected
univariable:  
eMr (95% Ci)
Multivariable†: 
eMr (95% Ci)
Observed/
expected
univariable: 
eMr (95% Ci)
Multivariable†: 
eMr 95% Ci)
Observed/
expected
univariable: 
eMr (95% Ci)
Multivariable†: 
eMr (95% Ci)
<1970 145/50.0 1 (ref) 1 (ref) 61/14.3 1 (ref) 1 (ref) 65/40.9 1 (ref) 1 (ref)
1970-79 74/16.7 0.5 (0.3 to 0.8) 0.9 (0.6 to 1.4) 48/5.2 0.8 (0.5 to 1.3) 1.0 (0.7 to 1.7) 55/45.2 0.4 (0.1 to 1.8) 0.7 (0.3 to 1.7)
1980-89 63/7.8 0.5 (0.3 to 0.7) 1.3 (0.8 to 2.0) 36/2.9 0.6 (0.4 to 1.0) 0.9 (0.5 to 1.6) 41/38.9 0.1 (0.0 to 33.7) 0.5 (0.2 to 1.5)
1990-2006 18/3.5 0.1 (0.1 to 0.2) 0.4 (0.2 to 0.6) 19/1.8 0.3 (0.2 to 0.5) 0.4 (0.2 to 0.8) 27/26.7 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
P for trend‡ <0.01 0.19 <0.01 0.01 <0.01 <0.01
EMR=excess mortality ratios.
*Includes deaths due to transportation accidents, falls, drowning, fire, suicide, etc.
†Adjusted for sex, first primary neoplasm type, age at diagnosis, and attained age.
‡Calculated using likelihood ratio tests to assess the effect of treatment period.
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bias in death certification inflating deaths from recur-
rence or progression is well known.20  Secondly, when 
we were uncertain about a particular cause of death 
we assigned it to recurrence or progression. Interest-
ingly, among those aged 50-59 years, 41% and 22% of 
excess deaths were due to subsequent primary neo-
plasms and circulatory causes, respectively, whereas 
the corresponding percentages for those aged 60 years 
or more were 31% and 37%. This study provides evi-
dence that as survivors age beyond 60 years, circula-
tory causes account for more excess deaths than 
subsequent primary neoplasms. This is not entirely 
surprising because in the general population, circula-
tory conditions account for substantially more deaths 
than neoplasms among those aged 60 years or more. 
Excess deaths due to non-neoplastic causes are likely 
attributable to late complications of treatment, as 
radiotherapy and chemotherapy have been associated 
with adverse circulatory,21-25 respiratory,26-28  endo-
crine,29 30  neurological,31 32  and other chronic health 
conditions.29  33
Putting the results into context
Over the treatment periods covered by this study, sur-
vival after almost all specific types of childhood can-
cer has improved substantially. For all childhood 
cancers combined, survival to five years has increased 
from 28% to 77% among those with a diagnosis before 
1970 and with a diagnosis from 1996 to 2000, respec-
tively.34  Successful treatment among those with a 
diagnosis before 1970 was attributable to surgery or 
radiotherapy, or both. Thereafter, chemotherapy of 
increasing complexity was introduced, leading to 
substantial improvements in survival of most types of 
childhood cancer not successfully treatable before 
1970. In the 1990s bone marrow transplantation with 
high dose chemotherapy and often total body irradia-
tion was introduced for those types of malignancy not 
previously responsive to conventional radiotherapy 
and chemotherapy, either as first line treatment or as 
second line treatment. Consequently, the proportion 
of those with a diagnosis of cancer in childhood sur-
viving to five years has increased substantially, but 
the intensity of treatment has in general increased to 
achieve this success. This raises two important ques-
tions. Firstly, are those reaching five year survival as a 
result of the increasingly aggressive treatments in 
more recent decades truly cured, or is there evidence 
that recurrence or progression is merely postponed? 
Secondly, is the more aggressive treatment introduced 
in more recent decades associated with an increase in 
number of excess deaths from further primary cancers 
or non-neoplastic causes among five year survivors? 
The evidence presented in table 7  is overwhelmingly 
reassuring in relation to both questions. Firstly, the 
excess number of deaths attributable to recurrence or 
progression subsequent to five year survival substan-
tially declines among those treated from 1990 to 2006, 
compared with those treated before 1970, for all CNS 
tumours, all types of leukaemia, and all types of lym-
phoma; for each of these diagnostic groups the excess 
number of deaths attributable to the original cancer is 
at most 40% among those treated from 1990 to 2006 
compared with those treated before 1970. Secondly, 
with the exception of further cancers after soft tissue 
sarcoma, there is no evidence that the excess number 
of deaths attributable to either further primary can-
cers or non-neoplastic causes among five year survi-
vors of each specific childhood cancer treated in more 
recent decades exceeds that observed among those 
treated earlier (table 7 ). In the past three decades, 
through recruitment to randomised clinical trials, 
there have been systematic efforts to reduce the risk of 
adverse health outcomes experienced by survivors of 
types of childhood cancer with good prognosis by 
modifying treatment regimens with the aim of main-
taining the levels of cure, but reducing the risk of long 
term toxicity. It is likely that such efforts have contrib-
uted to the absence of an increase in excess numbers 
of deaths either from further primary cancers or from 
non-neoplastic causes, for the specific childhood can-
cers reported in table 7, in relation to treatment 
period.
strengths and weaknesses of this study
This study of mortality in five year survivors of child-
hood cancer provides the most precise estimates of risk 
to date owing to the fact it includes more survivors and 
observed deaths than previously reported. Because of 
our study’s population based design, selection bias is 
minimised and results are generalisable to Great Brit-
ain. By including survivors who received a diagnosis 
across almost seven decades, our study provides an 
opportunity to assess mortality from the pre-chemo-
therapy period to modern treatments and protocols. 
Furthermore, owing to our long follow-up time, we pro-
vide results on the risk of mortality beyond 60 years of 
age. By aggregating these strengths, the results pre-
sented in this study provide evidence that the net 
impact of more modern treatments and associated care 
is to reduce the excess numbers of subsequent deaths 
overall, from recurrence or progression and from 
non-neoplastic causes.
A weakness of our study is the absence of detailed 
information on treatment, which prevented investiga-
tion of treatment types. Another potential weakness of 
this study is that vital status was obtained through data 
linkage. Although we used NHS number, first name, 
middle initial, current surname, and date of birth to 
link our cohort with the national death registry, unsuc-
cessful and incorrect linkage is possible. Unsuccessful 
attempts should be limited, however, as in our most 
recent linkage of approximately 16 500 survivors with a 
diagnosis from 1992 to 2006, 92.7% were automatched 
and a further 7.0% were matched manually, resulting in 
only 0.3% of the survivors missing a vital status. 
Finally, our study is limited by the fact that our death 
classification relied on the underlying cause of death 
as coded on the death certificate. Death certificates 
have been shown to be imperfect,35-39  and thus some 
degree of misclassification is inherent in our data. 
None the less, it is more likely that we have under-as-
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certained deaths due to non-neoplastic causes, which 
were largely the outcomes of interest in this study, as 
survivors of childhood cancer are more likely to be 
coded as having a neoplastic related death owing to 
their previous medical history.20 Thus, our results 
likely underestimated the risk of deaths due to 
non-neoplastic causes among survivors of childhood 
cancer, and so the real risks are likely to be even greater 
than stated in this report.
Future research
As treatment regimens for childhood cancer are con-
stantly evolving, reassessment of late effects in this 
population will be necessary. Although we observed 
significant declines in excess mortality among those 
with a more recent diagnosis, it will be important to 
assess with further follow-up whether the groups with 
most recent diagnoses remain at decreased risks. It is 
possible that death has only been delayed owing to 
increased awareness and surveillance of late effects, 
which could detect chronic health conditions earlier 
and in doing so potentially prolong life. 
This study also provides risk estimates among survi-
vors of childhood cancer aged 60 years or more, where 
circulatory causes were found to be the main contribu-
tor to the excess number of deaths observed. Although 
we controlled for sex, type of first primary neoplasm, 
age at diagnosis, treatment period, and attained age, 
our results are only applicable to survivors who are at 
least 60 years old at the time of study, which is largely 
survivors of CNS neoplasms, Hodgkin’s lymphoma, and 
soft tissue sarcoma (see supplementary eTable 2). These 
survivors are quite different from those with a more 
recent diagnosis as they had a diagnosis of cancer that 
could be cured through surgery or radiotherapy alone 
(astrocytoma, CNS primitive neuroectodermal tumour—
surgery and radiotherapy; early stage Hodgkin’s lym-
phoma—radiation; early stage soft tissue sarcoma—sur-
gery and radiation). As the five year cure rates across 
most types of first primary neoplasm did not improve 
substantially until the 1970s, reassessment of the mor-
tality risks in survivors beyond 60 years or more 
attained age will be necessary to determine the general-
isability of our results. However, as circulatory causes 
are by far the leading cause of death in the general pop-
ulation for those living beyond 60 years of age, we sus-
pect the findings presented in this study will also 
remain consistent for survivors with a more recent diag-
nosis.
Conclusions and implications
The net effects of changes in cancer treatments, and 
surveillance and management for late effects, after 
treatment during the period 1940 to 2006 is to reduce 
the excess number of deaths from both recurrence or 
progression and non-neoplastic causes among those 
treated more recently. We provide evidence that 
among survivors aged at least 60 years, 31% and 37% 
of excess numbers of deaths observed were due to sub-
sequent primary neoplasms and circulatory condi-
tions, respectively. The fact that the excess numbers of 
deaths due to circulatory causes exceeds the excess 
number of deaths due to subsequent primary neo-
plasms is unsurprising because in the general popula-
tion aged 60 years or more circulatory conditions 
account for substantially more deaths than neo-
plasms. The critically important message here for the 
evidence based surveillance aimed at preventing 
excess mortality and morbidity in survivors aged 60 
years or more is that circulatory disease overtakes sub-
sequent primary neoplasms as the leading cause of 
excess mortality; long term follow-up programmes 
must reflect this and target education, surveillance, 
and intervention appropriately.
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